Biosign Closes Acquisition of IBL Internet Business Logic Inc.

TORONTO, April 9, 2014 /CNW/ - Biosign Technologies Inc. (TSXV: BIO, the "Company") is pleased to announce that on March 31, 2014, the Company closed the acquisition of IBL Internet Business Logic Inc. The execution of the share purchase agreement was previously announced on December 31, 2013.

IBL Internet Business Logic Inc. is a Saint John New Brunswick-based developer of innovative clinic management software, used primarily by allied health clinics including physiotherapists, chiropractors and registered massage therapists. Unlike competing systems, the ClinicServer and PencilThat solutions are entirely cloud based, and are therefore both more flexible, and easier to install, learn & use. Over 900 clinicians currently pay Biosign a monthly fee to use IBL software, and by July 1, 2014 that number is projected to grow by 75%. We will drive further growth as we integrate ClinicServer with other Biosign software assets.

Biosign CEO Robert Kaul commented: "IBL Internet Business Logic Inc is a technology leader and boasts a very professional team. I'd like to extend a warm welcome the team at ClinicServer, we are happy they are joining the Biosign family."

About Biosign Technologies Inc.
Biosign Technologies Inc. (TSXV: BIO) provides automated, software enabled health information solutions including the Pulsewave^® Health Monitor and the Healthanywhere™ Patient monitoring / self-management platform. The Company's Pulsewave^® Health Monitor solution enables pulse wave data collection for cardiovascular clinical decision support and self-care, while its Healthanywhere™ solution offers industry-leading remote patient monitoring and patient centred care management. The Company also offers a number of cardiovascular screening programs for consumers under its Heart Friendly™ brand, including Heart Friendly™ Practice, Heart Friendly™ Dentist, and Heart Friendly™ Fitness. For more information on Biosign, please visit www.biosign.com

Forward-Looking Statements
This release contains forward-looking statements. Forward-looking statements, without limitation, may contain the words believes, expects, anticipates, estimates, intends, plans, or similar expressions. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions and Biosign's actual results could differ materially from those anticipated. Forward looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. In the context of any forward-looking information please refer to risk factors detailed in, as well as other information contained in the company's filings with Canadian securities regulators (www.sedar.com).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Biosign Technologies Inc.

Biosign Contact Information:
Robert Kaul
Chief Executive Officer
Biosign Technologies
Phone: [phone] ext. 201
Email: [email protected]